Return to Home Incidence > Table

Incidence Rates Table

Data Options

Incidence Rate Report by State

Oral Cavity & Pharynx (Late Stage^), 2016-2020

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Percentlate
State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank⋔
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late ascending
US (SEER+NPCR) 1 7.4 (7.4, 7.5) N/A 29,248 62.9
West Virginia 6 9.9 (9.3, 10.5) 1 (1, 3) 249 69.5
Vermont 6 8.6 (7.7, 9.6) 6 (1, 31) 75 68.9
Georgia 3 8.4 (8.2, 8.7) 8 (3, 16) 1,029 68.0
Massachusetts 3 7.8 (7.5, 8.1) 21 (13, 30) 693 67.5
Missouri 6 8.7 (8.4, 9.0) 5 (2, 14) 677 67.5
Kentucky 3 9.0 (8.7, 9.4) 2 (1, 8) 513 67.4
Rhode Island 6 7.4 (6.7, 8.1) 30 (9, 45) 105 67.3
Ohio 6 8.4 (8.2, 8.6) 10 (4, 17) 1,268 67.2
South Carolina 6 8.3 (7.9, 8.6) 13 (4, 22) 556 66.5
Louisiana 3 8.6 (8.2, 8.9) 7 (2, 17) 485 66.2
North Carolina 6 8.2 (7.9, 8.4) 14 (6, 22) 1,066 65.6
Oregon 6 7.9 (7.5, 8.2) 19 (9, 30) 430 65.5
Alaska 6 7.6 (6.8, 8.6) 22 (3, 45) 62 65.0
Michigan 6 7.6 (7.4, 7.9) 23 (17, 31) 995 64.9
Maine 6 9.0 (8.4, 9.6) 3 (1, 16) 179 64.8
Illinois 3 7.8 (7.6, 8.0) 20 (14, 28) 1,222 64.6
California 3 6.5 (6.4, 6.6) 44 (40, 46) 2,929 64.5
Pennsylvania 6 8.0 (7.8, 8.2) 16 (11, 24) 1,372 64.3
Mississippi 6 8.3 (7.9, 8.7) 12 (3, 25) 306 64.0
New York 3 7.2 (7.0, 7.3) 33 (27, 38) 1,775 64.0
Delaware 6 7.5 (6.8, 8.2) 29 (7, 44) 99 63.9
Wisconsin 6 7.9 (7.6, 8.2) 17 (9, 28) 608 63.8
Arkansas 6 8.8 (8.3, 9.2) 4 (2, 15) 330 63.7
Tennessee 6 8.2 (7.9, 8.4) 15 (6, 23) 700 63.5
Montana 6 7.6 (6.9, 8.3) 25 (6, 43) 108 63.4
New Jersey 3 7.2 (6.9, 7.4) 34 (25, 39) 822 63.4
New Hampshire 6 7.6 (7.0, 8.2) 24 (7, 39) 147 63.3
Connecticut 3 7.5 (7.1, 7.8) 27 (16, 37) 360 62.8
Maryland 6 6.9 (6.6, 7.1) 39 (30, 44) 517 62.5
Colorado 6 6.6 (6.3, 6.9) 42 (35, 46) 436 62.0
New Mexico 3 5.6 (5.2, 6.1) 47 (45, 49) 150 62.0
Virginia 6 7.0 (6.8, 7.2) 37 (28, 41) 735 61.9
District of Columbia 6 6.3 (5.4, 7.2) 45 (25, 49) 44 61.8
Hawaii 3 7.9 (7.3, 8.5) 18 (4, 36) 144 61.4
Kansas 6 7.1 (6.7, 7.5) 35 (22, 43) 249 60.9
Texas 3 6.7 (6.6, 6.9) 40 (36, 44) 2,048 60.6
Florida 6 8.4 (8.2, 8.5) 9 (5, 16) 2,509 60.1
Washington 5 7.3 (7.1, 7.6) 31 (22, 37) 670 59.7
Iowa 3 8.3 (7.9, 8.8) 11 (3, 23) 332 59.2
Arizona 6 5.3 (5.0, 5.5) 49 (46, 49) 478 58.6
Nebraska 6 7.5 (7.0, 8.0) 28 (13, 40) 170 58.2
Idaho 3 7.0 (6.5, 7.5) 38 (21, 46) 151 58.1
Oklahoma 6 7.5 (7.2, 7.9) 26 (15, 37) 353 57.7
South Dakota 6 7.0 (6.3, 7.8) 36 (14, 46) 75 57.2
Utah 3 5.4 (5.0, 5.8) 48 (45, 49) 155 56.9
Wyoming 6 6.1 (5.3, 7.0) 46 (27, 49) 44 56.6
North Dakota 6 7.2 (6.4, 8.1) 32 (7, 46) 64 55.9
Minnesota 6 6.6 (6.4, 6.9) 41 (34, 46) 463 53.2
Alabama 6 6.5 (6.3, 6.8) 43 (36, 46) 412 52.7
Puerto Rico 6 4.2 (3.9, 4.5) N/A 175 47.6
Indiana 6
data not available
N/A
data not available
data not available
Nevada 6
data not available
N/A
data not available
data not available
Notes:
Created by statecancerprofiles.cancer.gov on 05/30/2024 6:45 pm.

State Cancer Registries may provide more current or more local data.
Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.
⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. More information about methodology can be found on the CI*Rank website.

Data not available for this combination of data selections.

1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.
3 Source: SEER November 2022 submission. State Cancer Registry also receives funding from CDC's National Program of Cancer Registries.
5 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.
6 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).
Data not available for this combination of geography, cancer site, age, and race/ethnicity.

Data for the United States does not include data from Nevada.
Data for the United States does not include Puerto Rico.
CI*Rank data for Puerto Rico is not available.

Return to Top